Anthrax. Smallpox. Incurable and horrifying Ebola-related fevers. For two decades, while a fearful world prepared for nuclear winter, an elite team of Russian bioweaponeers began to till a new killing field: a bleak tract sown with powerful seeds of mass destruction—by doctors who had committed themselves to creating a biological Armageddon. Biohazard is the never-before-told story of Russia’s darkest, deadliest, and most closely guarded Cold War secret.
No one knows more about Russia’s astounding experiments with biowarfare than Ken Alibek. Now the mastermind behind Russia’s germ warfare effort reveals two decades of shocking breakthroughs . . . how Moscow’s leading scientists actually reengineered hazardous microbes to make them even more virulent . . . the secrets behind the discovery of an invisible, untraceable new class of biological agents just right for use in political assassinations . . . the startling story behind Russia’s attempt to turn a sample of the AIDS virus into the ultimate bioweapon. And in a chilling work of real-world intrigue, Biohazard offers us all a rare glimpse into a shadowy scientific underworld where doctors manufacture mass destruction, where witnesses to errors are silenced forever, and where ground zero is closer than we ever dared believe.
Ken Alibek was born in Kauchuk, Kazakhstan, in 1950. He holds a Ph.D. in microbiology for research and development of plague and tularemia biological weapons and a doctorate of science in biotechnology for developing the technology to manufacture anthrax on an industrial scale. He joined Biopreparat in 1975 and was its first deputy chief from 1988 to 1992. Since his defection to the United States in 1992, he has briefed U.S. military intelligence on biological weapons and created a graduate program in biodefense. He was also instrumental in the development of–and was vice dean of–the School of Science and Technology at Kazakhstan’s Nazarbayev University, and has since helped to establish Kazakhstan’s National Research Oncology Center jointly with University of Pittsburgh Medical Center.